Company IO Biotech, Inc.

Equities

IOBT

US4497781090

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:15:46 2024-05-24 pm EDT			5-day change	1st Jan Change
1.27 ^USD	-3.79%		-8.70%	-32.98%

May. 15	HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating	MT
May. 14	IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâs product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâs lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Number of employees: 68

Managers	Title	Age	Since
Mai-Britt Zocca FOU	Founder	56	14-11-30
Amy Sullivan DFI	Director of Finance/CFO	54	22-10-14
Eric Faulkner CTO	Chief Tech/Sci/R&D Officer	-	-
Qasim Ahmad CTO	Chief Tech/Sci/R&D Officer	-	-
Muhammad Al-Hajj CTO	Chief Tech/Sci/R&D Officer	53	21-04-30
Devin Smith CMP	Compliance Officer	56	23-01-22
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	21-09-30
Brian Burkavage AUD	Comptroller/Controller/Auditor	-	20-12-31
Dan Mannix LAW	General Counsel	-	21-09-30

Members of the board	Title	Age	Since
David Smith BRD	Director/Board Member	64	22-02-28
K. Hirth CHM	Chairman	72	16-08-31
Kathleen Glaub BRD	Director/Board Member	70	18-04-30
Christian Ellebæk Elling BRD	Director/Board Member	55	15-11-30
Mai-Britt Zocca FOU	Founder	56	14-11-30
Heidi Hunter BRD	Director/Board Member	66	23-08-10
Helen Collins BRD	Director/Board Member	62	Nov. 08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,880,914	65,726,129 ( 99.77 %)	0	99.77 %

Name	Equities	%	Valuation
Lundbeckfond Invest A/S 21.18 %	13,950,686	21.18 %	20 M $
Kurma Partners SA 10.35 %	6,821,133	10.35 %	10 M $
Vivo Capital LLC 9.371 %	6,173,439	9.371 %	9 M $
Novo Holdings A/S (Investment Company) 6.723 %	4,429,449	6.723 %	6 M $
HBM Partners AG (Investment Management) 5.987 %	3,944,492	5.987 %	6 M $
Stonepine Capital Management LLC 5.527 %	3,641,345	5.527 %	5 M $
Samsara Biocapital LLC 5.525 %	3,640,015	5.525 %	5 M $
PFM Health Sciences LP 3.554 %	2,341,107	3.554 %	3 M $
Morgan Stanley Capital Services LLC 3.335 %	2,197,234	3.335 %	3 M $
Marshall Wace LLP 3.196 %	2,105,262	3.196 %	3 M $

IO Biotech, Inc.

Ole Maaløes Vej 3

2200, Copenhagen

http://www.iobiotech.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.32 USD

Average target price

9.75 USD

Spread / Average Target

+638.64%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IO BIOTECH, INC.	-30.85%	86.96M
MODERNA, INC.	+66.20%	62.86B
IQVIA HOLDINGS INC.	-1.13%	41.38B
LONZA GROUP AG	+45.77%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+14.03%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.55%	18.9B
BIO-TECHNE CORPORATION	+4.22%	12.67B
UNITED THERAPEUTICS CORPORATION	+23.50%	12.27B
MEDPACE HOLDINGS, INC.	+28.41%	12.07B

Other Biotechnology & Medical Research